Specialty

This 52-week phase 3 atopic dermatitis (AD) study indicates that upadacitinib with topical corticosteroids has the potential to be a successful and well-tolerated long-term treatment option for people with moderate-to-severe atopic dermatitis. Atopic dermatitis (AD) causes skin-related disability and burden over the long run. Over the course of 20 to 30 years, most AD patients...

In patients with moderate-to-severe atopic dermatitis (AD), dupilumab significantly reduces hospitalization rates and hospitalization length related to AD. Atopic dermatitis (AD), a chronic inflammatory skin disease, may necessitate inpatient hospitalization for refractory cases, severe flares (exacerbations), and infections. A U.S. study also found that 18.9% of hospitalized individuals with a primary diagnosis of AD or...

Long-term nemolizumab therapy in patients with AD and moderate-to-severe pruritus significantly improves pruritus, AD, and quality of life. Pruritus is a distinguishing symptom of atopic dermatitis (AD), an inflammatory skin disorder that affects up to 25 percent of children and 5 percent of adults globally. The exact cause of pruritus in AD is unknown, but...

ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating ATTR-CM is, in most cases, significantly improved when it is discovered early, although this poses some unique challenges of its...

IL-6 levels have been found to correlate with other autoimmune conditions, and this study provides some evidence that it is also a biomarker of NMOSD disease activity. Currently, there are no widely accepted soluble markers for disease progression or activity of neuromyelitis optica spectrum disorder (NMOSD). This article, published in the Journal of Neuroimmunology, analyzed...

Managing food allergies in inner-city schools poses a unique challenge with many overlapping factors. The path toward an optimal solution requires addressing each of these in turn. Food allergies affect about 8% of children in the United States. Management of allergies usually involves both preventing allergic responses and treating allergic reactions, both of which provide...

Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends to have high morbidity, poor treatment outcomes, and high treatment expenditure. Recent advances in therapeutic strategies for ATTR-CM have shown...

ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM is caused by transthyretin (TTR) amyloid protein build ups in the myocardium and other organs, in most cases the peripheral...

Patients with NMOSD have increased COVID-19 risks, as determined by this meta-analysis. Individual susceptibility to COVID-19, as well as the ultimate outcome of the disease, can vary widely depending on comorbidities. This study, published in Multiple Sclerosis and Related Disorders, sought to determine the clinical features of COVID-19 in patients with neuromyelitis optica spectrum disorder...